Changes in Metastatic Castration Sensitive Prostate Cancer

Gürbüz, Mustafa; ÜRÜN, YÜKSEL

doi:10.4274/uob.galenos.2019.1407

Changes in Metastatic Castration Sensitive Prostate Cancer

Mustafa Gürbüz, (Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE)

Yüksel Ürün (Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKİYE)

Üroonkoloji Bülteni

1 0

Yıl: 2021 Cilt: 20 Sayı: 1 Sayfa Aralığı: 1 - 6 Metin Dili: İngilizce DOI: 10.4274/uob.galenos.2019.1407 İndeks Tarihi: 17-05-2022

Changes in Metastatic Castration Sensitive Prostate Cancer

Öz:

Prostate cancer is the second most common cancer in men worldwide, with approximately 1,276,106 new patients and 358,989 new deaths. Metastatic castrationsensitive prostate cancer may be de novo metastatic, but also it may be in the localized disease stage at the time of diagnosis, and may present as biochemical relapse and later metastatic disease over time. Purposes of metastatic castration-sensitive prostate cancer treatment are prolonging survival, improving quality of life and reducing complications. In this review, it is aimed to evaluate the current developments in metastatic castration-sensitive prostate cancer treatment.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worlwide for 36 centers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34.
3. Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol 2020;77:38-52.
4. Türkyılmaz M, Hacıkamiloğlu E, Baran Deniz E, et al. Türkiye kanser istatistikleri 2015. Türkiye Cumhuriyeti Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü, Ankara, 2018. Available: https://hsgm. saglik.gov.tr/depo/birimler/kanser-db/istatistik/Trkiye_Kanser_ statistikleri_2015.pdf
5. Machtens S, Schultheiss D, Kuczyk M, et al. The history of endocrine therapy of benign and malignant diseases of the prostate. World J Urol 2000;18:222-226.
6. Labrie F. Adrenal androgens and intracrinology. Semin Reprod Med 2004;22:299-309.
7. Azzouni F, Godo y A, Li Y, Mohler J. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol 2012;2012:530121.
8. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972;22:232-240.
9. Assikis VJ, Simons JW. Novel therapeutic strategies for androgenindependent prostate cancer: an update. Semin Oncol 2004;31:26-32.
10. Sweeney C, Chen Y, Carducci M, et al. Chemohormonal therapy versus hormonal therapy for hormone naive newly metastatic prostate cancer: ECOG-led randomized trial. Ann Oncol 2014;25(Suppl 4):iv256.
11. Moffat LE. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 1990;18 Suppl 3:26-27.
12. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132:566-577.
13. Schröder FH, Whelan P, De Reijke TM, et al. Members of the EORTC Genito-Urinary Group. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the “European Organization for Research and Treatment of Cancer” (EORTC) Protocol 30892. Eur Urol 2004;45:457-464.
14. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
15. Tannock IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
16. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 2015;373:737-746.
17. Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUGAFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149-158.
18. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163-1177.
19. Vale CL, Burdett S, Rydzewska LH, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and metaanalyses of aggregate data. Lancet Oncol 2016;17:243-256.
20. Yap TA, Carden P, Attard G, de Bono JS. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol 2008;8:449-457.
21. Fizazi K, Tran NP, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352-360.
22. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377:338-351.
23. San Tan P, Aguiar P, Haaland B, Lopes G. Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgendeprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis. Prostate Cancer Prostatic Dis 2018;21:516-523.
24. Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 2018;29:1235-1248.
25. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-790.
26. Amstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019;37:2974-2986.
27. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med 2019;381:121-131.
28. Chopra A, Georgieva M, Lopes G, et al. Abiraterone or Enzalutamide in Advanced Castration Resistant Prostate Cancer: An Indirect Comparison. Prostate 2017;77:639-646.
29. Al-Salama ZT. Apalutamide: First global approval. Drugs 2018;78:699-705.
30. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2019;381:13-24.
31. Diamond TH, Bucci J, Kersley JH, et al. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. J Urol 2004;172:529-532.
32. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
33. Scardino P. Update: NCCN prostate cancer clinical practice guidelines. J Natl Compr Canc Netw 2005;3 Suppl 1:S29-S33.
34. Boevé LMS, Hulshof MCCM, Vis AN, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol 2019;75:410-418.
35. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018;392:2353-2366.
36. Burdett S, Boeve LM, Ingleby FC, et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. Eur Urol 2019;76:115-124.
37. Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014;65:1058-1066. 38. Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol 2014;66:602-603.

APA	Gürbüz M, ÜRÜN Y (2021). Changes in Metastatic Castration Sensitive Prostate Cancer. , 1 - 6. 10.4274/uob.galenos.2019.1407
Chicago	Gürbüz Mustafa,ÜRÜN YÜKSEL Changes in Metastatic Castration Sensitive Prostate Cancer. (2021): 1 - 6. 10.4274/uob.galenos.2019.1407
MLA	Gürbüz Mustafa,ÜRÜN YÜKSEL Changes in Metastatic Castration Sensitive Prostate Cancer. , 2021, ss.1 - 6. 10.4274/uob.galenos.2019.1407
AMA	Gürbüz M,ÜRÜN Y Changes in Metastatic Castration Sensitive Prostate Cancer. . 2021; 1 - 6. 10.4274/uob.galenos.2019.1407
Vancouver	Gürbüz M,ÜRÜN Y Changes in Metastatic Castration Sensitive Prostate Cancer. . 2021; 1 - 6. 10.4274/uob.galenos.2019.1407
IEEE	Gürbüz M,ÜRÜN Y "Changes in Metastatic Castration Sensitive Prostate Cancer." , ss.1 - 6, 2021. 10.4274/uob.galenos.2019.1407
ISNAD	Gürbüz, Mustafa - ÜRÜN, YÜKSEL. "Changes in Metastatic Castration Sensitive Prostate Cancer". (2021), 1-6. https://doi.org/10.4274/uob.galenos.2019.1407

APA	Gürbüz M, ÜRÜN Y (2021). Changes in Metastatic Castration Sensitive Prostate Cancer. Üroonkoloji Bülteni, 20(1), 1 - 6. 10.4274/uob.galenos.2019.1407
Chicago	Gürbüz Mustafa,ÜRÜN YÜKSEL Changes in Metastatic Castration Sensitive Prostate Cancer. Üroonkoloji Bülteni 20, no.1 (2021): 1 - 6. 10.4274/uob.galenos.2019.1407
MLA	Gürbüz Mustafa,ÜRÜN YÜKSEL Changes in Metastatic Castration Sensitive Prostate Cancer. Üroonkoloji Bülteni, vol.20, no.1, 2021, ss.1 - 6. 10.4274/uob.galenos.2019.1407
AMA	Gürbüz M,ÜRÜN Y Changes in Metastatic Castration Sensitive Prostate Cancer. Üroonkoloji Bülteni. 2021; 20(1): 1 - 6. 10.4274/uob.galenos.2019.1407
Vancouver	Gürbüz M,ÜRÜN Y Changes in Metastatic Castration Sensitive Prostate Cancer. Üroonkoloji Bülteni. 2021; 20(1): 1 - 6. 10.4274/uob.galenos.2019.1407
IEEE	Gürbüz M,ÜRÜN Y "Changes in Metastatic Castration Sensitive Prostate Cancer." Üroonkoloji Bülteni, 20, ss.1 - 6, 2021. 10.4274/uob.galenos.2019.1407
ISNAD	Gürbüz, Mustafa - ÜRÜN, YÜKSEL. "Changes in Metastatic Castration Sensitive Prostate Cancer". Üroonkoloji Bülteni 20/1 (2021), 1-6. https://doi.org/10.4274/uob.galenos.2019.1407